DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-007/S-010, S-013
NDA 21-039/S-009, S-012

GlaxoSmithKline
Attention: Mr. Robert S. Watson
P.O. Box 13398
Five Moore Drive
Research Triangle Park
North Carolina, 27709

Dear Mr. Watson

Please refer to your supplemental new drug applications dated April 4, 2001, received April 5, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AGENERASE® CAPSULES and AGENERASE® Oral Solution.

We acknowledge receipt of your submissions dated May 9, 2001, August 30, 2001, September 12, 2001, September 24, 2001, October 31, 2001, November 30, 2001, December 21, 2001, and January 23, 2002.

These supplemental new drug applications provide for the inclusion of pharmacokinetic, safety, and dosing information on the co-administration of AGENERASE® Capsules/AGENERASE® Oral Solution with NORVIR® (ritonavir) in the AGENERASE® Capsules and AGENERASE® Oral Solution package inserts. AGENERASE® Capsules and AGENERASE® Oral Solution are indicated for the treatment of HIV-1 infection.

Additionally, please refer to your supplemental new drug applications dated October 11, 2001, received October 12, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AGENERASE® CAPSULES and AGENERASE® Oral Solution. These supplemental new drug applications provide for the inclusion of wording outlining the potential for redistribution/accumulation of body fat concurrent with the use of nucleoside analogues in the PRECAUTIONS and Patient Information tear off of the AGENERASE® CAPSULES and AGENERASE® Oral Solution package insert and patient package insert.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted January 23, 2002, patient package insert submitted January 23, 2002).

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 21-007/S-010, S-013, 21-039/S-009, S-012." Approval of these submissions by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have fulfilled the pediatric study requirement at this time.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Destry M. Sillivan, M.S., Regulatory Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Debra Birnkrant
2/5/02 03:52:25 PM
NDA 21-039, NDA 21-007